Page last updated: 2024-11-08

latrunculin a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

latrunculin A: 16-membered macrolide attached to 2-thiazolidinone moiety; from Red Sea sponge Latrunculia magnifica; see also latrunculin B; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

latrunculin A : A bicyclic macrolide natural product consisting of a 16-membered bicyclic lactone attached to the rare 2-thiazolidinone moiety. It is obtained from the Red Sea sponge Latrunculia magnifica and from the Fiji Islands sponge Cacospongia mycofijiensis. Latrunculin A inhibits actin polymerisation, microfilament organsation and microfilament-mediated processes. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID445420
CHEMBL ID404116
CHEBI ID69136
SCHEMBL ID12998892
MeSH IDM0112416

Synonyms (35)

Synonym
nsc-613011
NSC613011 ,
latrunculin a
76343-93-6
2-thiazolidinone,12-dimethyl-3-oxo-2,16- dioxabicyclo[13.3.1]nonadeca-4,8,10-trien-17-yl)-, [1r-[1r*,4z,8e,10z,12s*,15r*,17r*(r*)]]-
2-thiazolidinone, 4-[(1r,4z,8e,10z,12s,15r,17r)-17-hydroxy-5,12-dimethyl-3-oxo-2,16-dioxabicyclo[13.3.1]nonadeca-4,8,10-trien-17-yl]-, (4r)-
(4r)-4-[(1r,4s,5z,7e,11z,15r,17r)-17-hydroxy-4,11-dimethyl-13-oxo-14,18-dioxabicyclo[13.3.1]nonadeca-5,7,11-trien-17-yl]thiazolidin-2-one
(4r)-4-[(1r,4z,8e,10z,12s,15r,17r)-17-hydroxy-5,12-dimethyl-3-oxo-2,16-dioxabicyclo[13.3.1]nonadeca-4,8,10-trien-17-yl]-1,3-thiazolidin-2-one
DB02621
lat-a
lata
(+)-latrunculin a
latrunculin a, latrunculia magnifica
CHEMBL404116
chebi:69136 ,
2-thiazolidinone, 4-(17-hydroxy-5,12-dimethyl-3-oxo-2,16-dioxabicyclo(13.3.1)nonadeca-4,8,10-trien-17-yl)-, (1r*,4z,8e,10z,12s*,15r*,17r*(r*))-(+)-
srq9wwm084 ,
nsc 613011
unii-srq9wwm084
2-thiazolidinone, 4-((1r,4z,8e,10z,12s,15r,17r)-17-hydroxy-5,12-dimethyl-3-oxo-2,16-dioxabicyclo(13.3.1)nonadeca-4,8,10-trien-17-yl)-, (4r)-
latrunculin a [mi]
2-thiazolidinone, 4-(17-hydroxy-5,12-dimethyl-3-oxo-2,16-dioxabicyclo(13.3.1)nonadeca-4,8,10-trien-17-yl)-, (1r-(1r*,4z,8e,10z,12s*,15r*,17r*(r*)))-
latrunculin
SCHEMBL12998892
4-[(1r,4z,8e,10z,12s,15r, 17r)-17-hydroxy-5,12-dimethyl-3-oxo-2,16-dioxabicyclo[13.3.1]nonadeca-4,8,10-trien-17-yl)-2-thiazolidinone
HB0375
4-[(1r,4z,8e,10z,12s,15r, 17r)-17-hydroxy-5,12-dimethyl-3-oxo -2,16-dioxabicyclo[13.3.1]nonadeca-4,8,10-trien-17 -yl)-2-thiazolidinone
AKOS024457907
c22h31no5s
DTXSID90893488
Q4255014
bdbm65515
(r)-4-((1r,4z,8e,10z,12s,15r,17r)-17-hydroxy-5,12-dimethyl-3-oxo-2,16-dioxabicyclo[13.3.1]nonadeca-4,8,10-trien-17-yl)thiazolidin-2-one
CS-0012976
HY-16929

Research Excerpts

Overview

Latrunculin A (LatA) is a toxic natural product. LatA causes disruption of the actin cytoskeleton in many eukaryotic cells at submicromolar concentrations.

ExcerptReferenceRelevance
"Latrunculin A (LatA) is a toxic natural product that causes disruption of the actin cytoskeleton in many eukaryotic cells at submicromolar concentrations. "( An unexplained sequestration of latrunculin A is required in neutrophils for inhibition of actin polymerization.
Cassimeris, L; Pring, M; Zigmond, SH, 2002
)
2.04

Treatment

Latrunculin A treatment, actin and beta-dystroglycan binding domain deletion constructs, and co-immunoprecipitation assays demonstrate that mini-dyStrophin is firmly anchored to the sarcolemma. Treatment with latruncul in A abolished both, RVD and the accompanying rise of [Ca(2+)](i) after hypotonic stress.

ExcerptReferenceRelevance
"Latrunculin A treatment, actin and beta-dystroglycan binding domain deletion constructs, and co-immunoprecipitation assays demonstrate that mini-dystrophin is firmly anchored to the sarcolemma primarily through its connections to beta-dystroglycan, mimicking effects seen with wild type dystrophin."( Mini-dystrophin efficiently incorporates into the dystrophin protein complex in living cells.
Draviam, RA; Li, J; Wang, B; Watkins, SC; Xiao, X, 2006
)
1.06
"Latrunculin A treatment extended all stages from karyogamy to meiosis I."( F-actin distribution and function during sexual differentiation in Schizosaccharomyces pombe.
Egel, R; Hagan, IM; Nielsen, O; Petersen, J, 1998
)
1.02
"Treatment with latrunculin A abolishes the cardioprotective postconditioning effect, inducing morphological and structural changes in cardiac tissue, reducing F-actin staining and diminishing caveolae formation."( Actin-Cytoskeleton Drives Caveolae Signaling to Mitochondria during Postconditioning.
Chávez-Canales, M; Correa, F; de Los Heros, P; Enríquez-Cortina, C; Gil-Hernández, A; Hernández-Rizo, S; Ostolga-Chavarría, M; Román-Anguiano, N; Silva-Palacios, A; Soria-Castro, E; Zazueta, C, 2023
)
1.25
"Treatment with latrunculin A abolished both, RVD and the accompanying rise of [Ca(2+)](i) after hypotonic stress in TRPV4-transfected CHO cells."( Functional interaction of the cation channel transient receptor potential vanilloid 4 (TRPV4) and actin in volume regulation.
Becker, D; Bereiter-Hahn, J; Jendrach, M, 2009
)
0.69
"Treatment with latrunculin A to sequester globular-actin abolished cytoneme formation."( Interaction between activated chemokine receptor 1 and FcepsilonRI at membrane rafts promotes communication and F-actin-rich cytoneme extensions between mast cells.
Beer, F; Fifadara, NH; Ono, S; Ono, SJ, 2010
)
0.7
"Pretreatment with Latrunculin A changed the kinetics to a single exponential, slightly faster than the fast component of control cells (1.2 s)."( Spatial regulation of exocytic site and vesicle mobilization by the actin cytoskeleton.
Richards, DA; Wang, J, 2011
)
0.69
"Treatment with latrunculin A increases both of the relaxation time constants."( Cell relaxation after electrodeformation: effect of latrunculin A on cytoskeletal actin.
Ho, CM; Tan, W; Wong, PK, 2005
)
0.92
"Treatment with latrunculin A caused hyphal tip swelling without apparent effect on linear microtubule arrays."( Live-cell imaging of tubulin in the filamentous fungus Magnaporthe grisea treated with anti-microtubule and anti-microfilament agents.
Bourett, TM; Czymmek, KJ; DeZwaan, TM; Howard, RJ; Shao, Y; Sweigard, JA, 2005
)
0.67
"Pretreatment with latrunculin A prevented actin reorganization and the changes in fMLP-stimulated exocytosis induced by Hsp27 sequestration."( Heat shock protein 27 regulates neutrophil chemotaxis and exocytosis through two independent mechanisms.
Haribabu, B; Jala, VR; Jog, NR; McLeish, KR; Rane, MJ; Ward, RA, 2007
)
0.66

Dosage Studied

ExcerptRelevanceReference
" Dose-response studies show a good correlation between inhibition of actin polymerization and increased degranulation."( The role of actin microfilaments in the down-regulation of the degranulation response in RBL-2H3 mast cells.
Apgar, JR; Frigeri, L, 1999
)
0.3
" The perfusion system presented here is a simple, inexpensive device suited for analysis of drug dose-response and regeneration of single cells and arrays of cells."( Microfluidic perfusion system for culturing and imaging yeast cell microarrays and rapidly exchanging media.
Juncker, D; Li, H; Mirzaei, M; Nazarova, E; Pla-Roca, M; Safavieh, M; Safavieh, R; Vogel, J, 2010
)
0.36
" Interestingly, reducing the dosage of cofilin by half or expressing a phospho-mimetic mutant form, S3E, partially rescues the migration and protrusion defects of Rac-deficient border cells."( Regulation of cofilin phosphorylation and asymmetry in collective cell migration during morphogenesis.
Chen, J; Laski, F; Luo, J; Wan, P; Wu, J; Zhang, L, 2011
)
0.37
" Exposure to 50 or 100 pulses of 10 ns duration and 150 kV/cm in a single dosage approximately lowers average CHO cell elastic modulus by half, whereas latrunculin lowers it more than 75%."( Disruption of the actin cortex contributes to susceptibility of mammalian cells to nanosecond pulsed electric fields.
Ibey, BL; Kuipers, M; Roth, C; Thompson, GL; Tolstykh, G, 2014
)
0.4
"Biological cells can be characterized as "soft matter" with mechanical characteristics potentially modulated by external cues such as pharmaceutical dosage or fever temperature."( Chemoenvironmental modulators of fluidity in the suspended biological cell.
Maloney, JM; Van Vliet, KJ, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
toxinPoisonous substance produced by a biological organism such as a microbe, animal or plant.
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
actin polymerisation inhibitorAny substance that inhibits the polymerisation of the protein actin.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
oxabicycloalkane
thiazolidinone
macrolideA macrocyclic lactone with a ring of twelve or more members derived from a polyketide.
cyclic hemiketalA hemiacetal having the structure R2C(OH)OR (R =/= H), derived from a ketone by formal addition of an alcohol to the carbonyl group. The term 'cyclic hemiketals', once abandoned by IUPAC, has been reinstated as a subclass of hemiacetals.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ActinSaccharomyces cerevisiae S288CIC50 (µMol)0.07330.04000.16830.3800AID1794862
Hypoxia-inducible factor 1-alphaHomo sapiens (human)IC50 (µMol)15.85000.00072.46529.2100AID330402; AID330403
Endothelial PAS domain-containing protein 1Homo sapiens (human)IC50 (µMol)15.85000.00302.60028.5100AID330402; AID330403
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (98)

Processvia Protein(s)Taxonomy
positive regulation of chemokine-mediated signaling pathwayHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of signaling receptor activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
response to hypoxiaHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of DNA-templated transcriptionHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIHypoxia-inducible factor 1-alphaHomo sapiens (human)
response to reactive oxygen speciesHypoxia-inducible factor 1-alphaHomo sapiens (human)
angiogenesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
response to hypoxiaHypoxia-inducible factor 1-alphaHomo sapiens (human)
intracellular glucose homeostasisHypoxia-inducible factor 1-alphaHomo sapiens (human)
neural crest cell migrationHypoxia-inducible factor 1-alphaHomo sapiens (human)
epithelial to mesenchymal transitionHypoxia-inducible factor 1-alphaHomo sapiens (human)
embryonic placenta developmentHypoxia-inducible factor 1-alphaHomo sapiens (human)
B-1 B cell homeostasisHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of endothelial cell proliferationHypoxia-inducible factor 1-alphaHomo sapiens (human)
heart loopingHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of neuroblast proliferationHypoxia-inducible factor 1-alphaHomo sapiens (human)
chondrocyte differentiationHypoxia-inducible factor 1-alphaHomo sapiens (human)
glandular epithelial cell maturationHypoxia-inducible factor 1-alphaHomo sapiens (human)
connective tissue replacement involved in inflammatory response wound healingHypoxia-inducible factor 1-alphaHomo sapiens (human)
outflow tract morphogenesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
cardiac ventricle morphogenesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
lactate metabolic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of glycolytic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of DNA-templated transcriptionHypoxia-inducible factor 1-alphaHomo sapiens (human)
intracellular iron ion homeostasisHypoxia-inducible factor 1-alphaHomo sapiens (human)
signal transductionHypoxia-inducible factor 1-alphaHomo sapiens (human)
neuroblast proliferationHypoxia-inducible factor 1-alphaHomo sapiens (human)
lactationHypoxia-inducible factor 1-alphaHomo sapiens (human)
visual learningHypoxia-inducible factor 1-alphaHomo sapiens (human)
response to iron ionHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of gene expressionHypoxia-inducible factor 1-alphaHomo sapiens (human)
vascular endothelial growth factor productionHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of vascular endothelial growth factor productionHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of gene expressionHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of gene expressionHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of epithelial cell migrationHypoxia-inducible factor 1-alphaHomo sapiens (human)
response to muscle activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
axonal transport of mitochondrionHypoxia-inducible factor 1-alphaHomo sapiens (human)
neural fold elevation formationHypoxia-inducible factor 1-alphaHomo sapiens (human)
cerebral cortex developmentHypoxia-inducible factor 1-alphaHomo sapiens (human)
bone mineralizationHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of bone mineralizationHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayHypoxia-inducible factor 1-alphaHomo sapiens (human)
TOR signalingHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of TOR signalingHypoxia-inducible factor 1-alphaHomo sapiens (human)
intracellular oxygen homeostasisHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of chemokine productionHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of transforming growth factor beta2 productionHypoxia-inducible factor 1-alphaHomo sapiens (human)
collagen metabolic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
cellular response to oxidative stressHypoxia-inducible factor 1-alphaHomo sapiens (human)
embryonic hemopoiesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
insulin secretion involved in cellular response to glucose stimulusHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of insulin secretion involved in cellular response to glucose stimulusHypoxia-inducible factor 1-alphaHomo sapiens (human)
hemoglobin biosynthetic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of blood vessel endothelial cell migrationHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of erythrocyte differentiationHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of angiogenesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of growthHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIHypoxia-inducible factor 1-alphaHomo sapiens (human)
muscle cell cellular homeostasisHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of hormone biosynthetic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
digestive tract morphogenesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of nitric-oxide synthase activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
neuron apoptotic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
elastin metabolic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
intestinal epithelial cell maturationHypoxia-inducible factor 1-alphaHomo sapiens (human)
epithelial cell differentiation involved in mammary gland alveolus developmentHypoxia-inducible factor 1-alphaHomo sapiens (human)
iris morphogenesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
retina vasculature development in camera-type eyeHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of thymocyte apoptotic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
cellular response to interleukin-1Hypoxia-inducible factor 1-alphaHomo sapiens (human)
cellular response to hypoxiaHypoxia-inducible factor 1-alphaHomo sapiens (human)
dopaminergic neuron differentiationHypoxia-inducible factor 1-alphaHomo sapiens (human)
mesenchymal cell apoptotic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
hypoxia-inducible factor-1alpha signaling pathwayHypoxia-inducible factor 1-alphaHomo sapiens (human)
cellular response to virusHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of cytokine production involved in inflammatory responseHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of mitophagyHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of miRNA transcriptionHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of miRNA transcriptionHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathwayHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of aerobic respirationHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of reactive oxygen species metabolic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of protein neddylationHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of mesenchymal cell apoptotic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of transcription by RNA polymerase IIHypoxia-inducible factor 1-alphaHomo sapiens (human)
response to hypoxiaEndothelial PAS domain-containing protein 1Homo sapiens (human)
angiogenesisEndothelial PAS domain-containing protein 1Homo sapiens (human)
embryonic placenta developmentEndothelial PAS domain-containing protein 1Homo sapiens (human)
blood vessel remodelingEndothelial PAS domain-containing protein 1Homo sapiens (human)
regulation of heart rateEndothelial PAS domain-containing protein 1Homo sapiens (human)
epithelial cell maturationEndothelial PAS domain-containing protein 1Homo sapiens (human)
response to oxidative stressEndothelial PAS domain-containing protein 1Homo sapiens (human)
mitochondrion organizationEndothelial PAS domain-containing protein 1Homo sapiens (human)
signal transductionEndothelial PAS domain-containing protein 1Homo sapiens (human)
visual perceptionEndothelial PAS domain-containing protein 1Homo sapiens (human)
erythrocyte differentiationEndothelial PAS domain-containing protein 1Homo sapiens (human)
lung developmentEndothelial PAS domain-containing protein 1Homo sapiens (human)
norepinephrine metabolic processEndothelial PAS domain-containing protein 1Homo sapiens (human)
mRNA transcription by RNA polymerase IIEndothelial PAS domain-containing protein 1Homo sapiens (human)
surfactant homeostasisEndothelial PAS domain-containing protein 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIEndothelial PAS domain-containing protein 1Homo sapiens (human)
myoblast fate commitmentEndothelial PAS domain-containing protein 1Homo sapiens (human)
multicellular organismal-level iron ion homeostasisEndothelial PAS domain-containing protein 1Homo sapiens (human)
cellular response to hypoxiaEndothelial PAS domain-containing protein 1Homo sapiens (human)
positive regulation of cold-induced thermogenesisEndothelial PAS domain-containing protein 1Homo sapiens (human)
regulation of protein neddylationEndothelial PAS domain-containing protein 1Homo sapiens (human)
regulation of transcription by RNA polymerase IIEndothelial PAS domain-containing protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (23)

Processvia Protein(s)Taxonomy
DNA-binding transcription factor activity, RNA polymerase II-specificHypoxia-inducible factor 1-alphaHomo sapiens (human)
sequence-specific DNA bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificHypoxia-inducible factor 1-alphaHomo sapiens (human)
cis-regulatory region sequence-specific DNA bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
DNA-binding transcription activator activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
DNA-binding transcription repressor activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
transcription coactivator bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificHypoxia-inducible factor 1-alphaHomo sapiens (human)
p53 bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
DNA-binding transcription factor activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
protein bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
nuclear receptor bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
enzyme bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
protein kinase bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
protein domain specific bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
ubiquitin protein ligase bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
histone deacetylase bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
protein heterodimerization activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
Hsp90 protein bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
E-box bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
transcription regulator activator activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
sequence-specific DNA bindingEndothelial PAS domain-containing protein 1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingEndothelial PAS domain-containing protein 1Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificEndothelial PAS domain-containing protein 1Homo sapiens (human)
transcription coactivator bindingEndothelial PAS domain-containing protein 1Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificEndothelial PAS domain-containing protein 1Homo sapiens (human)
protein bindingEndothelial PAS domain-containing protein 1Homo sapiens (human)
protein heterodimerization activityEndothelial PAS domain-containing protein 1Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingEndothelial PAS domain-containing protein 1Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingEndothelial PAS domain-containing protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
nucleusHypoxia-inducible factor 1-alphaHomo sapiens (human)
nucleoplasmHypoxia-inducible factor 1-alphaHomo sapiens (human)
cytoplasmHypoxia-inducible factor 1-alphaHomo sapiens (human)
cytosolHypoxia-inducible factor 1-alphaHomo sapiens (human)
nuclear bodyHypoxia-inducible factor 1-alphaHomo sapiens (human)
nuclear speckHypoxia-inducible factor 1-alphaHomo sapiens (human)
motile ciliumHypoxia-inducible factor 1-alphaHomo sapiens (human)
axon cytoplasmHypoxia-inducible factor 1-alphaHomo sapiens (human)
chromatinHypoxia-inducible factor 1-alphaHomo sapiens (human)
euchromatinHypoxia-inducible factor 1-alphaHomo sapiens (human)
protein-containing complexHypoxia-inducible factor 1-alphaHomo sapiens (human)
RNA polymerase II transcription regulator complexHypoxia-inducible factor 1-alphaHomo sapiens (human)
nucleoplasmEndothelial PAS domain-containing protein 1Homo sapiens (human)
cytosolEndothelial PAS domain-containing protein 1Homo sapiens (human)
nuclear speckEndothelial PAS domain-containing protein 1Homo sapiens (human)
chromatinEndothelial PAS domain-containing protein 1Homo sapiens (human)
transcription regulator complexEndothelial PAS domain-containing protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (53)

Assay IDTitleYearJournalArticle
AID330393Antimetastatic activity in human PC3M cells expressing calcitonin assessed as inhibition of invasion at 100 nM by Matrigel barrier assay2008Journal of natural products, Mar, Volume: 71, Issue:3
Latrunculin A and its C-17-O-carbamates inhibit prostate tumor cell invasion and HIF-1 activation in breast tumor cells.
AID330396Antimetastatic activity in human PC3M cells expressing calcitonin assessed as inhibition calcitonin-induced reorganization of actin fibers at 50 nM by Matrigel barrier assay2008Journal of natural products, Mar, Volume: 71, Issue:3
Latrunculin A and its C-17-O-carbamates inhibit prostate tumor cell invasion and HIF-1 activation in breast tumor cells.
AID554741Inhibition of Candida krusei ABC1 expressed in Saccharomyces cerevisiae isolate ADdelta at 0.24 nM2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei.
AID638667Antiproliferative activity against human MDA-MB-435 cells assessed as cell viability after 96 hrs by CellTiter-Glo luminescence assay2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Natural product libraries to accelerate the high-throughput discovery of therapeutic leads.
AID454045Antimicrobial activity against Candida albicans by twofold dilution method2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Semisynthetic latrunculin B analogs: studies of actin docking support a proposed mechanism for latrunculin bioactivity.
AID514313Suppression of MAPK10 gene in Saccharomyces cerevisiae harboring cdc28-as transfected with 2 uM expression vector TEplac195 at 5 uM using multicopy pool construction by TAG microarray2008Nature chemical biology, Aug, Volume: 4, Issue:8
An integrated platform of genomic assays reveals small-molecule bioactivities.
AID1895040Inhibition of actin (unknown origin) polymerization at 1 uM incubated for 20 mins in presence of ATP by ELISA analysis relative to control2021European journal of medicinal chemistry, Aug-05, Volume: 220Discovery of cytotoxic natural products from Red Sea sponges: Structure and synthesis.
AID330399Antimetastatic activity in human PC3M cells expressing calcitonin assessed as decreased cell migration at 500 nM by spheroid disintegration assay relative to control2008Journal of natural products, Mar, Volume: 71, Issue:3
Latrunculin A and its C-17-O-carbamates inhibit prostate tumor cell invasion and HIF-1 activation in breast tumor cells.
AID397146Inhibition of PKC-mediated mouse EL-4.IL-2 cells adherence by MTT assay1993Journal of natural products, Jun, Volume: 56, Issue:6
Evaluation of marine sponge metabolites for cytotoxicity and signal transduction activity.
AID330403Inhibition of 1,10-phenanthroline-induced HIF1 activation in human T47D cells by cell based reporter gene assay2008Journal of natural products, Mar, Volume: 71, Issue:3
Latrunculin A and its C-17-O-carbamates inhibit prostate tumor cell invasion and HIF-1 activation in breast tumor cells.
AID330397Cytotoxicity against human PC3M cells2008Journal of natural products, Mar, Volume: 71, Issue:3
Latrunculin A and its C-17-O-carbamates inhibit prostate tumor cell invasion and HIF-1 activation in breast tumor cells.
AID514314Suppression of MAPK10 gene in Saccharomyces cerevisiae harboring cdc28-as at 2.5 uM using deletion pool construction by TAG microarray2008Nature chemical biology, Aug, Volume: 4, Issue:8
An integrated platform of genomic assays reveals small-molecule bioactivities.
AID344907Cytotoxicity against human MDA-MB-435 cells 48 hrs by SRB assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Interrogating the bioactive pharmacophore of the latrunculin chemotype by investigating the metabolites of two taxonomically unrelated sponges.
AID1550512Anti-invasive activity against mouse NIH/3T3 cells transfected with human AdoMetDC cDNA in sense orientation assessed as inhibition of cell invasion at 100 ng/ml incubated for 1 weeks by matrigel-based microscopic analysis relative to control2019European journal of medicinal chemistry, May-15, Volume: 170Multi-target compounds acting in cancer progression: Focus on thiosemicarbazone, thiazole and thiazolidinone analogues.
AID638670Antiproliferative activity against human U937 cells assessed as cell viability after 96 hrs by CellTiter-Glo luminescence assay2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Natural product libraries to accelerate the high-throughput discovery of therapeutic leads.
AID511779Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
3D-QSAR studies of latrunculin-based actin polymerization inhibitors using CoMFA and CoMSIA approaches.
AID397144Cytotoxicity against mouse P388 cells after 48 hrs by MTT assay1993Journal of natural products, Jun, Volume: 56, Issue:6
Evaluation of marine sponge metabolites for cytotoxicity and signal transduction activity.
AID1550514Anti-invasive activity against human MDA-MB-231 cells at 30 nM by crystal violet staining based Boyden chamber assay relative to control2019European journal of medicinal chemistry, May-15, Volume: 170Multi-target compounds acting in cancer progression: Focus on thiosemicarbazone, thiazole and thiazolidinone analogues.
AID344909Disruption of microfilament in rat A10 cells at 9 uM after 18 hrs using DAPI staining by fluorescence microscopy2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Interrogating the bioactive pharmacophore of the latrunculin chemotype by investigating the metabolites of two taxonomically unrelated sponges.
AID638664Stabilization of microtubule in human HeLa cells at 20 ug/ml after 24 hrs by Hoechst staining-based fluorescence microscopic analysis2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Natural product libraries to accelerate the high-throughput discovery of therapeutic leads.
AID1711894Induction of aplyronine A-actin complex-tubulin (unknown origin) protein-protein interaction assessed as association of actin-aplyronine A-tubulin complex by SPR analysis2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Analysis of the aplyronine A-induced protein-protein interaction between actin and tubulin by surface plasmon resonance.
AID330395Antimetastatic activity in human PC3M cells expressing calcitonin assessed as shrinkage of actin fibers at 50 nM by Matrigel barrier assay2008Journal of natural products, Mar, Volume: 71, Issue:3
Latrunculin A and its C-17-O-carbamates inhibit prostate tumor cell invasion and HIF-1 activation in breast tumor cells.
AID344908Ratio of IC50 for human MDA-MB-435 cells to IC50 for human HCT116 cells2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Interrogating the bioactive pharmacophore of the latrunculin chemotype by investigating the metabolites of two taxonomically unrelated sponges.
AID397145Cytotoxicity against mouse EL-4.IL-2 cells after 3 to 4 days by Trypan blue exclusion test1993Journal of natural products, Jun, Volume: 56, Issue:6
Evaluation of marine sponge metabolites for cytotoxicity and signal transduction activity.
AID344906Cytotoxicity against human HCT116 cells after 3 days by trypan blue assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Interrogating the bioactive pharmacophore of the latrunculin chemotype by investigating the metabolites of two taxonomically unrelated sponges.
AID330405Cell viability in human T47D cells at 30 uM by SRB method2008Journal of natural products, Mar, Volume: 71, Issue:3
Latrunculin A and its C-17-O-carbamates inhibit prostate tumor cell invasion and HIF-1 activation in breast tumor cells.
AID638665Induction of microfilament disruption in human HeLa cells at 20 ug/ml after 24 hrs by Hoechst staining-based fluorescence microscopic analysis2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Natural product libraries to accelerate the high-throughput discovery of therapeutic leads.
AID638668Antiproliferative activity against human HT-29 cells assessed as cell viability after 96 hrs by CellTiter-Glo luminescence assay2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Natural product libraries to accelerate the high-throughput discovery of therapeutic leads.
AID503638Binding affinity to rabbit skeletal muscle monomeric actin by isothermal calorimetric method2005Nature chemical biology, Dec, Volume: 1, Issue:7
Actin is the primary cellular receptor of bistramide A.
AID330402Inhibition of hypoxia-induced HIF1 activation in human T47D cells by cell based reporter gene assay2008Journal of natural products, Mar, Volume: 71, Issue:3
Latrunculin A and its C-17-O-carbamates inhibit prostate tumor cell invasion and HIF-1 activation in breast tumor cells.
AID1895039Inhibition of actin (unknown origin) polymerization at 100 nM incubated for 20 mins in presence of ATP by ELISA analysis relative to control2021European journal of medicinal chemistry, Aug-05, Volume: 220Discovery of cytotoxic natural products from Red Sea sponges: Structure and synthesis.
AID454046Antimicrobial activity against Aspergillus flavus NRRL 501 by twofold dilution method2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Semisynthetic latrunculin B analogs: studies of actin docking support a proposed mechanism for latrunculin bioactivity.
AID344913Cytotoxicity against mouse Colon 38 cells at 1.9 uM by disk diffusion soft agar colony formation assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Interrogating the bioactive pharmacophore of the latrunculin chemotype by investigating the metabolites of two taxonomically unrelated sponges.
AID381588Reversal of reduction of Lck Tyr394 phosphorylation in resting C57BL/6 mouse T cells at 20 uM by Western blot2007The Journal of biological chemistry, Nov-30, Volume: 282, Issue:48
Lateral compartmentalization of T cell receptor versus CD45 by galectin-N-glycan binding and microfilaments coordinate basal and activation signaling.
AID1895038Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay2021European journal of medicinal chemistry, Aug-05, Volume: 220Discovery of cytotoxic natural products from Red Sea sponges: Structure and synthesis.
AID503640Inhibition of actin polymerization2005Nature chemical biology, Dec, Volume: 1, Issue:7
Actin is the primary cellular receptor of bistramide A.
AID381591Reduction of Lck Tyr394 phosphorylation in resting C57BL/6 mouse T cells at 20 uM by Western blot2007The Journal of biological chemistry, Nov-30, Volume: 282, Issue:48
Lateral compartmentalization of T cell receptor versus CD45 by galectin-N-glycan binding and microfilaments coordinate basal and activation signaling.
AID638669Antiproliferative activity against human H522-T1 cells assessed as cell viability after 96 hrs by CellTiter-Glo luminescence assay2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Natural product libraries to accelerate the high-throughput discovery of therapeutic leads.
AID1550513Anti-invasive activity against mouse NIH/3T3 cells transfected with human AdoMetDC cDNA in antisense orientation assessed as inhibition of cell invasion at 100 ng/ml incubated for 1 weeks by matrigel-based microscopic analysis relative to control2019European journal of medicinal chemistry, May-15, Volume: 170Multi-target compounds acting in cancer progression: Focus on thiosemicarbazone, thiazole and thiazolidinone analogues.
AID397142Cytotoxicity against human A549 cells after 48 hrs by MTT assay1993Journal of natural products, Jun, Volume: 56, Issue:6
Evaluation of marine sponge metabolites for cytotoxicity and signal transduction activity.
AID1410160Induction of morphological changes in rat 3Y1 cells assessed as protrusions in cell membrane at 1.9 uM measured after 5 mins to 48 hrs by IncuCyte live cell imaging method2018Journal of natural products, 04-27, Volume: 81, Issue:4
Miuramides A and B, Trisoxazole Macrolides from a Mycale sp. Marine Sponge That Induce a Protrusion Phenotype in Cultured Mammalian Cells.
AID330398Antimetastatic activity in human PC3M cells expressing calcitonin assessed as decreased cell disaggregation at 500 nM by spheroid disaggregation assay relative to control2008Journal of natural products, Mar, Volume: 71, Issue:3
Latrunculin A and its C-17-O-carbamates inhibit prostate tumor cell invasion and HIF-1 activation in breast tumor cells.
AID397141Antitumor activity against human A549 cells xenografted in mouse at 0.3 mg/kg relative to control1993Journal of natural products, Jun, Volume: 56, Issue:6
Evaluation of marine sponge metabolites for cytotoxicity and signal transduction activity.
AID397151Toxicity in human A549 cells xenografted mouse at 0.3 mg/kg1993Journal of natural products, Jun, Volume: 56, Issue:6
Evaluation of marine sponge metabolites for cytotoxicity and signal transduction activity.
AID1895041Inhibition of actin (unknown origin) polymerization incubated for 20 mins in presence of ATP by ELISA analysis2021European journal of medicinal chemistry, Aug-05, Volume: 220Discovery of cytotoxic natural products from Red Sea sponges: Structure and synthesis.
AID454044Antimicrobial activity against Saccharomyces cerevisiae NRRL Y2034 by twofold dilution method2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Semisynthetic latrunculin B analogs: studies of actin docking support a proposed mechanism for latrunculin bioactivity.
AID397143Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay1993Journal of natural products, Jun, Volume: 56, Issue:6
Evaluation of marine sponge metabolites for cytotoxicity and signal transduction activity.
AID638666Antitrypanosomal activity against Trypanosoma brucei brucei clone 427-221a assessed as growth inhibition after 40 hrs by ATP-bioluminescence assay2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Natural product libraries to accelerate the high-throughput discovery of therapeutic leads.
AID402935Disruption of actin cytoskeleton in rat A10 cells upto 10 ug/ml by rhodamine-phalloidin assay2004Journal of natural products, Jun, Volume: 67, Issue:6
A new dimension to the biosynthetic products isolated from the sponge Negombata magnifica.
AID1895037Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay2021European journal of medicinal chemistry, Aug-05, Volume: 220Discovery of cytotoxic natural products from Red Sea sponges: Structure and synthesis.
AID1711895Induction of aplyronine A-actin complex-tubulin (unknown origin) protein-protein interaction assessed as actin-aplyronine A-tubulin ternary complex formation by SPR analysis2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Analysis of the aplyronine A-induced protein-protein interaction between actin and tubulin by surface plasmon resonance.
AID330394Antimetastatic activity in human PC3M cells expressing calcitonin assessed as inhibition calcitonin-induced invasion at 100 nM by Matrigel barrier assay2008Journal of natural products, Mar, Volume: 71, Issue:3
Latrunculin A and its C-17-O-carbamates inhibit prostate tumor cell invasion and HIF-1 activation in breast tumor cells.
AID1794862Liquid growth assay from Article 10.1021/acschembio.7b00385: \\Direct Interaction of Chivosazole F with Actin Elicits Cell Responses Similar to Latrunculin A but Distinct from Chondramide.\\2017ACS chemical biology, 09-15, Volume: 12, Issue:9
Direct Interaction of Chivosazole F with Actin Elicits Cell Responses Similar to Latrunculin A but Distinct from Chondramide.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (574)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (1.22)18.7374
1990's42 (7.32)18.2507
2000's309 (53.83)29.6817
2010's196 (34.15)24.3611
2020's20 (3.48)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.32

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.32 (24.57)
Research Supply Index6.37 (2.92)
Research Growth Index5.67 (4.65)
Search Engine Demand Index58.03 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (39.32)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (0.69%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other579 (99.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]